# Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

> **NCT02421354** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Hepatomegaly
- Myelofibrosis Transformation in Essential Thrombocythemia
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- Primary Myelofibrosis
- Splenomegaly

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02421354
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-14
- **Primary completion:** 2018-04-13
- **Final completion:** 2018-04-13
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02421354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02421354, "Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02421354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*